Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 2, 2012, Pages 315-320

  Cole, P E ^a   Schwarz, A J ^b   Schmidt, M E ^c  

^a Imagepace   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 FLUORO 3 [3 [4 (5 METHOXY 4 PYRIMIDINYL) 1 PIPERAZINYL]PROPYL] 1H INDOLE; APREPITANT; ARIPIPRAZOLE; BAPINEUZUMAB; DONEPEZIL; N METHYL 4 PIPERIDYL ACETATE C 11; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL PIPERIDIN 4 YL PROPIONATE C 11; OLANZAPINE; PLACEBO; QUETIAPINE; R 317573; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; RISPERIDONE; RIVASTIGMINE; SETOPERONE; UNCLASSIFIED DRUG; VOLINANSERIN; ZIPRASIDONE;

ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL RESEARCH; DISEASE MARKER; DRUG DISTRIBUTION; DRUG TARGETING; HUMAN; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS;

BIOLOGICAL MARKERS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; NEUROIMAGING;

EID: 84855948839     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.286     Document Type: Article

References (40)

1. Bergström, M. et al. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry 55, 1007-1012 (2004). (Pubitemid 38581916)
2. Warr, D.G. et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 23, 2822-2830 (2005). (Pubitemid 46179473)
3. Keller, M. et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry 59, 216-223 (2006). (Pubitemid 43208967)
4. Yokoi, F. et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27, 248-259 (2002). (Pubitemid 34692591)
5. Mace, S. & Taylor, D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 23, 773-780 (2009).
6. Christian, B.T. et al. Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. J. Pharmacol. Exp. Ther. 279, 325-331 (1996). (Pubitemid 27166928)
7. Tauscher, J., Jones, C., Remington, G., Zipursky, R.B. & Kapur, S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol. Psychiatry 7, 317-321 (2002). (Pubitemid 34280640)
8. Gefvert, O., Bergström, M., Långström, B., Lundberg, T., Lindström, L. & Yates, R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl.) 135, 119-126 (1998). (Pubitemid 28055494)
9. Gründer, G. et al. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology 17, 175-185 (1997). (Pubitemid 27365958)
10. Vernaleken, I. et al. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F] Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J. Clin. Psychopharmacol. 28, 608-617 (2008).
11. Abanades, S. et al. Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J. Cereb. Blood Flow Metab. 31, 944-952 (2011).
12. Shinotoh, H., Fukushi, K., Nagatsuka, S. & Irie, T. Acetylcholinesterase imaging: its use in therapy evaluation and drug design. Curr. Pharm. Des. 10, 1505-1517 (2004). (Pubitemid 38559763)
13. Shiraishi, T. et al. Estimation of plasma IC50 of donepezil hydrochloride for brain acetylcholinesterase inhibition in monkey using N-[11C] methylpiperidin-4-yl acetate ([11C]MP4A) and PET. Neuropsychopharmacology 30, 2154-2161 (2005). (Pubitemid 41643966)
14. Laruelle, M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J. Cereb. Blood Flow Metab. 20, 423-451 (2000). (Pubitemid 30164887)
15. Endres, C.J. et al. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies. J. Cereb. Blood Flow Metab. 17, 932-942 (1997). (Pubitemid 27396581)
16. Potkin, S.G. et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J. Neuropsychopharmacol. 4, 223-230 (2001). (Pubitemid 34101518)
17. Honey, G.D., O'loughlin, C., Turner, D.C., Pomarol-Clotet, E., Corlett, P.R. & Fletcher, P.C. The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: implications for pharmacological modelling of core symptoms of schizophrenia. Neuropsychopharmacology 31, 413-423 (2006). (Pubitemid 43113405)
18. Patin, A. & Hurlemann, R. Modulating amygdala responses to emotion: evidence from pharmacological fMRI. Neuropsychologia 49, 706-717 (2011).
19. Schmidt, M.E. et al. Dose-dependent effects of the CRF(1) receptor antagonist R317573 on regional brain activity in healthy male subjects. Psychopharmacology (Berl.) 208, 109-119 (2010).
20. Upadhyay, J. et al. Imaging Drugs with and without Clinical Analgesic Efficacy. Neuropsychopharmacology 36, 2659-2673 (2011).
21. Långsjö, J.W. et al. Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology 99, 614-623 (2003). (Pubitemid 37051976)
22. Långsjö, J.W. et al. Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology 100, 1065-1071 (2004). (Pubitemid 38541959)
23. Deakin, J.F., Lees, J., McKie, S., Hallak, J.E., Williams, S.R. & Dursun, S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 65, 154-164 (2008). (Pubitemid 351214314)
24. Tauscher, J.T. & Schwarz, A.J. Imaging Biomarkers and Methods in Translational Medicine. In Translational Medicine and Drug Discovery (eds. Krishna, R. & Littman, B.) pp. 222-264 (Cambridge University Press, Cambridge, UK, 2011).
25. Dubois, B. et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746 (2007). (Pubitemid 47058377)
26. Albert, M.S. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers. Dement. 7, 270-279 (2011).
27. Jack, C.R. Jr et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9, 119-128 (2010).
28. Någren, K., Halldin, C. & Rinne, J.O. Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 37, 1575-1593 (2010).
29. Bobinski, M. et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 95, 721-725 (2000).
30. McEvoy, L.K. et al.; Alzheimer's Disease Neuroimaging Initiative. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 24, 269-277 (2010).
31. Rinne, J.O. et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 9, 363-372 (2010).
32. Sperling, R.A. et al. Amyloid-related imaging abnormalities in amyloidmodifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers. Dement. 7, 367-385 (2011).
33. Joshi, A., Koeppe, R.A. & Fessler, J.A. Reducing between scanner differences in multi-center PET studies. Neuroimage 46, 154-159 (2009).
34. DeLorenzo, C., Kumari, J.S.D., Mann, J.J., & Parsey, R.V. In vivo variation in metabotropic glutamate receptor subtype 5 binding using positron emission tomography and [11C]ABP688. J. Cereb. Blood Flow Metab 31, 2169-2180 (2011).
35. Bennett, C.M. & Miller, M.B. How reliable are the results from functional magnetic resonance imaging? Ann. N.Y. Acad. Sci. 1191, 133-155 (2010).
36. Honey, G. & Bullmore, E. Human pharmacological MRI. Trends Pharmacol. Sci. 25, 366-374 (2004). (Pubitemid 38829490)
37. Iannetti, G.D. & Wise, R.G. BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn. Reson. Imaging 25, 978-988 (2007). (Pubitemid 47081371)
38. Weiner, M.W. et al.; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers. Dement. 6, 202-11.e7 (2010).
39. Borsook, D., Bleakman, D., Hargreaves, R., Upadhyay, J., Schmidt, K.F. & Becerra, L. A 'BOLD' experiment in defining the utility of fMRI in drug development. Neuroimage 42, 461-466 (2008).
40. Buckler, A.J., Bresolin, L., Dunnick, N.R. & Sullivan, D.C.; Group. A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. Radiology 258, 906-914 (2011).